Treatment of painful diabetic neuropathy

Saad Javed, Ioannis N. Petropoulos, Uazman Alam, Rayaz Malik

Research output: Contribution to journalReview article

54 Citations (Scopus)

Abstract

Painful diabetic neuropathy (PDN) is a debilitating consequence of diabetes that may be present in as many as one in five patients with diabetes. The objective assessment of PDN is difficult, making it challenging to diagnose and assess in both clinical practice and clinical trials. No single treatment exists to prevent or reverse neuropathic changes or to provide total pain relief. Treatment of PDN is based on three major approaches: intensive glycaemic control and risk factor management, treatments based on pathogenetic mechanisms, and symptomatic pain management. Clinical guidelines recommend pain relief in PDN through the use of antidepressants such as amitriptyline and duloxetine, the γ-aminobutyric acid analogues gabapentin and pregabalin, opioids and topical agents such as capsaicin. Of these medications, duloxetine and pregabalin were approved by the US Food and Drug Administration (FDA) in 2004 and tapentadol extended release was approved in 2012 for the treatment of PDN. Proposed pathogenetic treatments include α-lipoic acid (stems reactive oxygen species formation), benfotiamine (prevents vascular damage in diabetes) and aldose-reductase inhibitors (reduces flux through the polyol pathway). There is a growing need for studies to evaluate the most potent drugs or combinations for the management of PDN to maximize pain relief and improve quality of life. A number of agents are potential candidates for future use in PDN therapy, including Nav 1.7 antagonists, N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists.

Original languageEnglish
Pages (from-to)15-28
Number of pages14
JournalTherapeutic Advances in Chronic Disease
Volume6
Issue number1
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Diabetic Neuropathies
Pain
Therapeutics
Angiotensin II Type 2 Receptor Blockers
N-Type Calcium Channels
Aminobutyrates
Thioctic Acid
Aldehyde Reductase
Amitriptyline
Capsaicin
Risk Management
Calcium Channel Blockers
Nerve Growth Factor
Drug Combinations
United States Food and Drug Administration
Pain Management
Opioid Analgesics
Antidepressive Agents
Blood Vessels
Reactive Oxygen Species

Keywords

  • Diabetes mellitus
  • Management
  • Neuropathy

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Treatment of painful diabetic neuropathy. / Javed, Saad; Petropoulos, Ioannis N.; Alam, Uazman; Malik, Rayaz.

In: Therapeutic Advances in Chronic Disease, Vol. 6, No. 1, 2015, p. 15-28.

Research output: Contribution to journalReview article

Javed, Saad ; Petropoulos, Ioannis N. ; Alam, Uazman ; Malik, Rayaz. / Treatment of painful diabetic neuropathy. In: Therapeutic Advances in Chronic Disease. 2015 ; Vol. 6, No. 1. pp. 15-28.
@article{2dbefaf30efc48b09cf8ba05b445118c,
title = "Treatment of painful diabetic neuropathy",
abstract = "Painful diabetic neuropathy (PDN) is a debilitating consequence of diabetes that may be present in as many as one in five patients with diabetes. The objective assessment of PDN is difficult, making it challenging to diagnose and assess in both clinical practice and clinical trials. No single treatment exists to prevent or reverse neuropathic changes or to provide total pain relief. Treatment of PDN is based on three major approaches: intensive glycaemic control and risk factor management, treatments based on pathogenetic mechanisms, and symptomatic pain management. Clinical guidelines recommend pain relief in PDN through the use of antidepressants such as amitriptyline and duloxetine, the γ-aminobutyric acid analogues gabapentin and pregabalin, opioids and topical agents such as capsaicin. Of these medications, duloxetine and pregabalin were approved by the US Food and Drug Administration (FDA) in 2004 and tapentadol extended release was approved in 2012 for the treatment of PDN. Proposed pathogenetic treatments include α-lipoic acid (stems reactive oxygen species formation), benfotiamine (prevents vascular damage in diabetes) and aldose-reductase inhibitors (reduces flux through the polyol pathway). There is a growing need for studies to evaluate the most potent drugs or combinations for the management of PDN to maximize pain relief and improve quality of life. A number of agents are potential candidates for future use in PDN therapy, including Nav 1.7 antagonists, N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists.",
keywords = "Diabetes mellitus, Management, Neuropathy",
author = "Saad Javed and Petropoulos, {Ioannis N.} and Uazman Alam and Rayaz Malik",
year = "2015",
doi = "10.1177/2040622314552071",
language = "English",
volume = "6",
pages = "15--28",
journal = "Therapeutic Advances in Chronic Disease",
issn = "2040-6223",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment of painful diabetic neuropathy

AU - Javed, Saad

AU - Petropoulos, Ioannis N.

AU - Alam, Uazman

AU - Malik, Rayaz

PY - 2015

Y1 - 2015

N2 - Painful diabetic neuropathy (PDN) is a debilitating consequence of diabetes that may be present in as many as one in five patients with diabetes. The objective assessment of PDN is difficult, making it challenging to diagnose and assess in both clinical practice and clinical trials. No single treatment exists to prevent or reverse neuropathic changes or to provide total pain relief. Treatment of PDN is based on three major approaches: intensive glycaemic control and risk factor management, treatments based on pathogenetic mechanisms, and symptomatic pain management. Clinical guidelines recommend pain relief in PDN through the use of antidepressants such as amitriptyline and duloxetine, the γ-aminobutyric acid analogues gabapentin and pregabalin, opioids and topical agents such as capsaicin. Of these medications, duloxetine and pregabalin were approved by the US Food and Drug Administration (FDA) in 2004 and tapentadol extended release was approved in 2012 for the treatment of PDN. Proposed pathogenetic treatments include α-lipoic acid (stems reactive oxygen species formation), benfotiamine (prevents vascular damage in diabetes) and aldose-reductase inhibitors (reduces flux through the polyol pathway). There is a growing need for studies to evaluate the most potent drugs or combinations for the management of PDN to maximize pain relief and improve quality of life. A number of agents are potential candidates for future use in PDN therapy, including Nav 1.7 antagonists, N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists.

AB - Painful diabetic neuropathy (PDN) is a debilitating consequence of diabetes that may be present in as many as one in five patients with diabetes. The objective assessment of PDN is difficult, making it challenging to diagnose and assess in both clinical practice and clinical trials. No single treatment exists to prevent or reverse neuropathic changes or to provide total pain relief. Treatment of PDN is based on three major approaches: intensive glycaemic control and risk factor management, treatments based on pathogenetic mechanisms, and symptomatic pain management. Clinical guidelines recommend pain relief in PDN through the use of antidepressants such as amitriptyline and duloxetine, the γ-aminobutyric acid analogues gabapentin and pregabalin, opioids and topical agents such as capsaicin. Of these medications, duloxetine and pregabalin were approved by the US Food and Drug Administration (FDA) in 2004 and tapentadol extended release was approved in 2012 for the treatment of PDN. Proposed pathogenetic treatments include α-lipoic acid (stems reactive oxygen species formation), benfotiamine (prevents vascular damage in diabetes) and aldose-reductase inhibitors (reduces flux through the polyol pathway). There is a growing need for studies to evaluate the most potent drugs or combinations for the management of PDN to maximize pain relief and improve quality of life. A number of agents are potential candidates for future use in PDN therapy, including Nav 1.7 antagonists, N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists.

KW - Diabetes mellitus

KW - Management

KW - Neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84919629929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919629929&partnerID=8YFLogxK

U2 - 10.1177/2040622314552071

DO - 10.1177/2040622314552071

M3 - Review article

VL - 6

SP - 15

EP - 28

JO - Therapeutic Advances in Chronic Disease

JF - Therapeutic Advances in Chronic Disease

SN - 2040-6223

IS - 1

ER -